| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.046 | 0.1 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.071 | 0.1 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |